Hearts & Minds Blog

A Closer Look – June 2018

Tim Mayleben

President and Chief Executive Officer

As we approach the halfway point in 2018, our Lipid Management Team remains confident and encouraged by the consistently positive… more

Help with Understanding Liver Function Test Increases: From the Lipid Management Team

Tim Mayleben

President and Chief Executive Officer

We recently announced positive results from our first pivotal phase 3 study (Study 4 or the 048 study) of bempedoic… more

Reflecting on a Focused 2017 and Looking Ahead to a Transformational 2018

Tim Mayleben

President and Chief Executive Officer

The past year was marked by tremendous progress for our bempedoic acid-based franchise – perhaps most importantly the achievement of… more

Important Bempedoic Acid-Based Franchise Progress Updates

Tim Mayleben

President and Chief Executive Officer

Last week was exciting for us at Esperion as we reported on tremendous progress achieved in enrolling patients for our… more

The Bempedoic Acid / Ezetimibe Combo Pill: Our Leading Complementary, Non-statin, Oral Therapy

Marianne Andreach

Senior Vice President, Strategic Marketing and Product Planning

This week we announced a major milestone: the U.S. Food and Drug Administration (FDA) confirmed the regulatory pathway to approval… more